Skip to main content
QuestionsResearchTagsGuidelinesLeaderboard
tachyDx Research Portal

Research Portal

Every paper is generated from a real clinical discussion on tachyDx, peer-reviewed by verified physicians, and published with a unique TDX identifier. All contributors are credited.

DOIs registered viaCrossref
Published26Under ReviewFlagged

20 papers

TDX-2026-00026

Low-Titer Group O Whole Blood Resuscitation in Civilian Massive Hemorrhage: An Evidence Synthesis and Implementation Review

Massive hemorrhage remains a leading cause of preventable death in trauma. Traditional resuscitation protocols, often based on 1:1:1 component therapy (packed red blood cells, fresh frozen plasma, platelets), aim to mitigate trauma-induced coagulopathy. However, logistical challenges and delays associated with component preparation have prompted exploration of alternative strategies. Low-titer group O whole blood (LTOWB) has emerged as a promising option, offering a physiologically balanced resuscitation product. This paper synthesizes expert clinical perspectives and recent trial data regarding the transition to LTOWB in civilian trauma centers. Findings indicate that a hybrid approach, utilizing LTOWB for initial resuscitation units, can accelerate balanced resuscitation and improve hemostatic parameters. While logistical hurdles such as shelf life and inventory management persist, strategies for mitigation have been developed. Furthermore, LTOWB significantly reduces administrative errors and simplifies resuscitation protocols in high-stress environments. The role of dried plasma as a pre-hospital adjunct, particularly in settings with prolonged transport times or challenging cold chain logistics, is also discussed. The collective evidence suggests that LTOWB represents a valuable advancement in massive hemorrhage resuscitation, warranting careful consideration for integration into institutional protocols.

A physician-only Q&A platform where verified medical doctors share clinical knowledge, debate evidence, and build the knowledge base the world needs.

Powered by

Platform

  • Questions
  • Research
  • Tags
  • Guidelines
  • Leaderboard
  • Report a Bug

Ecosystem

  • Teams
  • Sponsors
  • Hiring
  • Publishing
  • CME
  • Data

Company

  • About
  • Support
  • Privacy Policy
  • Terms of Service
  • Contact

© 2026 Aethryva Deeptech Pvt Ltd. All rights reserved.

Crossref Member
2 contributors 82 votes 9 Apr 2026

TDX-2026-00025

Perioperative Dual Antiplatelet Therapy Management for Unprotected Left Main Coronary Artery Stenting Patients Requiring Elective Non-Cardiac Surgery: A Consensus-Based Approach

Patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES) require dual antiplatelet therapy (DAPT) to prevent stent thrombosis, a potentially catastrophic event. For unprotected left main coronary artery (ULMCA) PCI, guideline-recommended DAPT duration is typically 12 months. However, the need for elective non-cardiac surgery within this period presents a significant clinical dilemma, balancing the high risk of stent thrombosis if DAPT is prematurely discontinued against the increased bleeding risk during surgery if antiplatelets are continued. This paper synthesizes expert opinions from a clinical Q&A platform regarding the optimal management of a 71-year-old male who underwent ULMCA PCI with a Synergy everolimus-eluting stent 5 months prior and now requires an elective right hemicolectomy for well-differentiated adenocarcinoma. The consensus emphasizes delaying surgery to at least 9 months post-PCI if oncologically feasible. If surgery cannot be delayed, a bridging strategy with intravenous cangrelor is recommended, alongside aspirin continuation, meticulous perioperative monitoring, and a multidisciplinary team approach involving cardiology, oncology, surgery, and anesthesiology. This expert consensus highlights the critical need for individualized risk assessment, shared decision-making, and adherence to established protocols while acknowledging the limitations of current evidence specifically for ULMCA PCI in this high-risk scenario.

3 contributors 118 votes 9 Apr 2026

TDX-2026-00024

Optimal Sequencing of Immunotherapy for Pediatric B-Cell Acute Lymphoblastic Leukemia with Second Relapse Post-Allogeneic Hematopoietic Stem Cell Transplantation: A Clinical Consensus

Pediatric B-cell acute lymphoblastic leukemia (B-ALL) with second relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents a highly challenging clinical scenario with limited curative options. This paper synthesizes expert clinical opinion regarding the optimal sequencing and selection of novel immunotherapies, specifically tisagenlecleucel (CAR-T cell therapy) and blinatumomab (CD19/CD3 bispecific T-cell engager), for a 6-year-old female presenting with a second marrow relapse 14 months post-transplant. The discussion addresses critical considerations including blast burden management, manufacturing timelines, and potential toxicities in a heavily pre-treated patient. A consensus emerged favoring a strategy of bridging with blinatumomab to reduce blast burden, followed by definitive tisagenlecleucel. This approach leverages the immediate availability and debulking potential of blinatumomab to optimize conditions for CAR-T cell therapy, which offers superior long-term remission rates. The paper also explores the role of inotuzumab ozogamicin and discusses logistical challenges in diverse healthcare settings. This synthesis provides practical guidance for clinicians navigating complex treatment decisions in this ultra-high-risk patient population, emphasizing evidence-based sequencing to maximize therapeutic efficacy and minimize adverse events.

2 contributors 65 votes 9 Apr 2026

TDX-2026-00023

Antifibrotic Therapy in Progressive Rheumatoid Arthritis-Associated Interstitial Lung Disease with a Usual Interstitial Pneumonia Pattern: Expert Perspectives on Treatment Selection and Monitoring

Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) represents a significant cause of morbidity and mortality in patients with rheumatoid arthritis, particularly when presenting with a usual interstitial pneumonia (UIP) pattern and demonstrating progressive fibrosing characteristics. This paper synthesizes expert opinions from a clinical Q&A discussion regarding the management of a 58-year-old female with progressive RA-ILD (UIP pattern) despite immunosuppression. The primary clinical dilemma revolves around the selection between nintedanib and pirfenidone, the continuation of background immunosuppression, and optimal monitoring strategies. Expert consensus favored nintedanib as a first-line antifibrotic due to robust evidence from the INBUILD trial, particularly within the UIP subgroup. However, an alternative perspective highlighted pirfenidone's potential anti-inflammatory properties and institutional experience in connective tissue disease-associated ILD. Both experts strongly advocated for the continuation of mycophenolate, citing the potential for subclinical inflammation and the risks of disease flare or acceleration upon withdrawal. A comprehensive monitoring protocol incorporating FVC, 6-minute walk distance, patient-reported outcomes, and advanced techniques like home spirometry was recommended. This synthesis underscores the complexities of managing progressive RA-ILD, emphasizing evidence-based antifibrotic selection, judicious immunosuppression, and multi-modal monitoring to optimize patient outcomes.

2 contributors 58 votes 9 Apr 2026

TDX-2026-00022

Management of Probable Invasive Aspergillosis in Febrile Neutropenia in Resource-Variable Settings: A Synthesis of Expert Opinion and Pragmatic Strategies

Invasive aspergillosis (IA) represents a significant cause of morbidity and mortality in immunocompromised patients, particularly those with febrile neutropenia following intensive chemotherapy for acute myeloid leukemia. Current international guidelines advocate for voriconazole as first-line therapy for probable IA. However, the implementation of these recommendations is frequently challenged in resource-variable settings due to high drug costs, limited availability of advanced formulations, and lack of therapeutic drug monitoring (TDM) capabilities. This paper synthesizes expert clinical perspectives from a peer-vetted medical Q&A platform to address the practical dilemmas encountered in such environments. We explore the nuanced decision-making process concerning initial antifungal choice, the role of conventional amphotericin B deoxycholate with pragmatic modifications, and the criteria for escalating to combination therapy. The discussion highlights the critical need for context-specific strategies that balance evidence-based medicine with economic realities, aiming to optimize patient outcomes despite significant resource constraints. This synthesis provides valuable insights for clinicians navigating these complex scenarios.

2 contributors 75 votes 9 Apr 2026

TDX-2026-00021

Transjugular Intrahepatic Portosystemic Shunt (TIPS) versus Serial Large-Volume Paracentesis for Refractory Ascites in Cirrhosis with MELD 18: A Clinical Decision Analysis and Evidence Synthesis

Patients with advanced cirrhosis frequently develop refractory ascites, a significant cause of morbidity and mortality. Management options include serial large-volume paracentesis (LVP) and transjugular intrahepatic portosystemic shunt (TIPS). This paper synthesizes expert clinical perspectives and current literature to address the optimal management strategy for a 56-year-old male with alcohol-related cirrhosis, Child-Pugh C, and a MELD score of 18, experiencing refractory ascites requiring frequent LVP. The discussion focuses on the efficacy, safety, and transplant implications of TIPS compared to LVP. Evidence from meta-analyses and real-world cohorts suggests TIPS offers superior ascites control and potential transplant-free survival benefits, particularly in carefully selected patients. While a MELD score of 18 approaches a critical threshold for increased post-TIPS mortality, factors such as sustained abstinence, absence of current hepatic encephalopathy, and technical feasibility favor TIPS in this specific case. The interaction of TIPS with liver transplant candidacy and surgical complexity is also explored, indicating minimal adverse impact. This analysis underscores the importance of individualized risk-benefit assessment in managing refractory ascites at the MELD 18 threshold, advocating for TIPS with a tailored protocol to mitigate risks and improve patient outcomes while awaiting liver transplantation.

2 contributors 62 votes 9 Apr 2026

TDX-2026-00020

DWI-FLAIR Mismatch and Large Vessel Occlusion in Wake-Up Stroke: A Synthesis of Expert Opinion and Evidence from a Clinical Case Discussion

Background: Wake-up stroke (WUS) presents a significant challenge in acute ischemic stroke management due to unknown symptom onset time, complicating eligibility for time-sensitive reperfusion therapies. Imaging-based selection, particularly diffusion-weighted imaging (DWI) and fluid-attenuated inversion recovery (FLAIR) mismatch, has expanded treatment windows for intravenous thrombolysis (IVT), while advanced perfusion imaging guides mechanical thrombectomy (MT) in large vessel occlusion (LVO). This paper synthesizes expert clinical decision-making in a complex WUS case with DWI-FLAIR mismatch and LVO, integrating current evidence. Methods: This academic paper formalizes a clinical Q&A discussion from the tachyDx platform, involving two verified stroke neurologists and receiving 96 community peer votes. The discussion centered on a 67-year-old female with WUS, left hemiplegia, NIHSS 14, right M1 occlusion, DWI-FLAIR mismatch, and a large penumbra on CT perfusion. Results: Both experts advocated for immediate bridging IVT followed by MT. Divergence arose in IVT dosing: one expert recommended standard 0.9 mg/kg alteplase, citing potential for maximum thrombolytic effect in LVO, while the other preferred 0.6 mg/kg, aligning with regional protocols and improved safety profiles. Both acknowledged the role of good collaterals in delaying FLAIR changes, supporting the validity of the DWI-FLAIR mismatch. The patient achieved TICI 2c reperfusion and significant neurological improvement. Conclusions: This case highlights the evolving consensus on aggressive reperfusion strategies for WUS with favorable imaging. It underscores the ongoing debate regarding optimal IVT dosing in the context of bridging therapy for LVO, emphasizing the need for individualized treatment guided by comprehensive imaging and patient-specific factors.

2 contributors 96 votes 9 Apr 2026

TDX-2026-00019

Management of Right Ventricular Dysfunction and Weaning Protocols for Veno-Venous Extracorporeal Membrane Oxygenation in COVID-19 Acute Respiratory Distress Syndrome: A Clinical Consensus Initiative

Veno-venous extracorporeal membrane oxygenation (VV-ECMO) provides crucial life support for severe acute respiratory distress syndrome (ARDS), including that caused by COVID-19. Weaning from VV-ECMO presents complex challenges, particularly concerning persistent right ventricular (RV) dysfunction, which can complicate decannulation decisions. This paper synthesizes expert clinical perspectives on VV-ECMO weaning criteria, focusing on RV assessment, sweep gas trial protocols, and the utility of inhaled pulmonary vasodilators. Utilizing a community peer-review platform, two critical care physicians provided detailed protocols and insights, which were subsequently validated by 84 peer votes. Key findings indicate a pragmatic approach to RV dysfunction, where mild residual impairment may be acceptable if gas exchange and hemodynamic stability are maintained. Staged sweep gas trials, extending up to 6 hours, are advocated, with continuous monitoring of respiratory mechanics, gas exchange, and hemodynamic parameters. The use of inhaled iloprost as a bridge therapy for residual pulmonary hypertension during decannulation was also explored. This initiative highlights the variability in current clinical practice and provides a consensus-driven framework to guide VV-ECMO weaning in patients with COVID-19 ARDS and RV dysfunction, emphasizing individualized patient assessment and a multidisciplinary approach.

2 contributors 84 votes 9 Apr 2026

TDX-2026-00018

Immune Checkpoint Inhibitor Rechallenge After Grade 3 Myocarditis in Metastatic Melanoma: A Community Peer-Reviewed Clinical Consensus and Management Framework

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, yet they are associated with immune-related adverse events (irAEs), including potentially fatal myocarditis. Current guidelines universally recommend permanent discontinuation of ICIs following grade 3 or 4 myocarditis. This consensus paper addresses the critical clinical dilemma of managing progressive metastatic melanoma in a patient who achieved an excellent initial response to pembrolizumab but subsequently developed grade 3 myocarditis, which fully resolved. Utilizing a community peer-review platform involving two expert oncologists and 91 peer votes, a nuanced framework for considering ICI rechallenge was developed. The framework emphasizes stringent criteria, including complete resolution of myocarditis, lack of alternative effective therapies, and life-threatening cancer with prior ICI response, alongside comprehensive patient counseling and intensive cardio-oncology monitoring. Strategies discussed include switching to anti-CTLA4 monotherapy, reduced-dose anti-PD1 rechallenge, and the potential role of prophylactic abatacept or pre-rechallenge endomyocardial biopsy. While acknowledging the significant risks, including a reported 30-60% recurrence rate of myocarditis, the consensus highlights that in highly selected cases with limited alternatives, a carefully managed rechallenge may be considered under strict multidisciplinary oversight. This paper provides an evidence-informed approach to navigate this complex clinical scenario, balancing oncologic benefit with critical cardiac safety.

2 contributors 91 votes 9 Apr 2026

TDX-2026-00017

Desensitization Strategies for Highly Sensitized Kidney Transplant Candidates with High-Titer Donor-Specific Antibodies: A Clinical Consensus and Evidence Review

Highly sensitized kidney transplant candidates, characterized by elevated calculated panel reactive antibody (cPRA) and high-titer donor-specific antibodies (DSA), face significant barriers to transplantation. This paper synthesizes expert clinical practice and current evidence regarding desensitization protocols for such challenging cases. Utilizing a community peer-reviewed clinical Q&A platform (tachyDx), expert opinions from two verified physicians, supported by 71 community votes, were analyzed to address critical questions concerning desensitization protocols for mean fluorescence intensity (MFI) >10,000, the role of imlifidase, and acceptable MFI thresholds for transplantation. **Background:** Highly sensitized kidney transplant candidates, often with a history of failed transplants, experience prolonged wait times and increased risk of antibody-mediated rejection (AMR). Effective desensitization protocols are crucial for expanding transplant access in this population. **Methods:** A clinical scenario involving a 34-year-old female with ESRD, cPRA 98%, and multiple high-titer DSAs (MFI up to 14,500) against a potential living donor was presented on the tachyDx platform. Two board-certified nephrology and transplant medicine specialists provided detailed responses, which were then peer-voted by 71 community physicians. This paper formally synthesizes these expert recommendations and integrates them with established medical literature. **Results:** A modified Johns Hopkins desensitization protocol, incorporating bortezomib, dexamethasone, plasmapheresis, IVIG, and rituximab, was proposed for MFI >10,000, demonstrating a 4/6 success rate in achieving transplantable MFI levels. Imlifidase (IdeS) was identified as a transformative rescue strategy, capable of rapidly cleaving IgG antibodies, with reported conversion rates to negative crossmatch exceeding 90% in clinical trials. Critical MFI thresholds for acceptable risk were defined as <5,000 for Class I and <3,000 for Class II DSA (particularly DQ), coupled with negative flow cytometry and C1q binding assays. DQ antibodies were highlighted as a significant concern due to their strong association with AMR. **Conclusions:** Effective management of highly sensitized kidney transplant candidates requires multi-agent desensitization strategies, judicious use of novel agents like imlifidase, and stringent MFI thresholds. Individualized protocols and close post-transplant monitoring are essential to mitigate the risk of AMR and improve graft outcomes in this complex patient population.

2 contributors 71 votes 9 Apr 2026

TDX-2026-00016

Optimizing Potassium Replacement and Insulin Initiation in Diabetic Ketoacidosis with Initial Hypokalemia: A Peer-Reviewed Clinical Consensus

Background: Diabetic ketoacidosis (DKA) is a severe metabolic emergency characterized by hyperglycemia, ketonemia, and acidosis. Despite the extracellular shift of potassium (K+) in acidosis, initial hypokalemia is observed in a significant proportion of DKA patients, indicating a profound total body K+ deficit. The timing of insulin initiation in such cases presents a critical clinical dilemma, balancing the urgent need for acidosis correction against the risk of precipitous K+ decline and subsequent cardiac arrhythmias. Methods: This consensus paper synthesizes expert opinion from two verified physicians within the tachyDx peer-review community, supported by 72 community peer votes. The discussion focused on a 28-year-old male presenting with DKA and initial serum K+ of 3.1 mEq/L. Key areas of inquiry included the aggressiveness and route of K+ replacement, concurrent K+ infusion rates with insulin, and the role of phosphate and magnesium supplementation. Results: A consensus emerged advocating for aggressive K+ replacement (e.g., 40 mEq KCl via central line over 1 hour) prior to insulin initiation, with a recommended threshold of K+ ≥ 3.5 mEq/L. Central venous access was preferred for high-rate infusions, with peripheral alternatives outlined. Concurrent K+ infusion at 20-40 mEq/hr was advised during insulin therapy, targeting serum K+ of 4.0-5.0 mEq/L. Modified insulin dosing (0.05 units/kg/hr) was suggested for K+ < 3.5 mEq/L. The importance of magnesium monitoring and replacement, alongside judicious potassium phosphate use for hypophosphatemia, was emphasized. Bicarbonate administration was generally discouraged. Conclusions: This peer-reviewed consensus provides practical, evidence-informed guidance for managing initial hypokalemia in DKA. The recommendations prioritize patient safety by mitigating arrhythmia risk while facilitating timely DKA resolution, offering a refined approach to electrolyte management in this complex clinical scenario.

2 contributors 72 votes 6 Apr 2026

TDX-2026-00015

Diagnostic Framework for Fever of Unknown Origin in Immunocompetent Adults: A Peer-Reviewed Clinical Consensus

Background: Fever of Unknown Origin (FUO) in immunocompetent adults represents a significant diagnostic challenge, often requiring extensive investigation despite initial comprehensive workup. The lack of specific localizing symptoms and the broad differential diagnosis necessitate a systematic, tiered approach to avoid diagnostic delays and inappropriate empirical treatments. This paper synthesizes expert clinical opinions on the subsequent diagnostic steps following an unrevealing initial evaluation. Methods: This consensus paper was developed from a clinical Q&A discussion on the tachyDx community platform, involving three verified physicians (an internist, an infectious disease specialist, and an oncologist) and garnering 60 community peer votes. The original clinical scenario involved a 42-year-old female presenting with four weeks of fever, weight loss, and night sweats, with an extensive negative initial workup. Expert responses were analyzed and synthesized to formulate a structured diagnostic pathway. Results: Key recommendations for second-tier investigations include 18F-FDG PET/CT, which demonstrates a diagnostic yield of approximately 50% and guides targeted biopsies. Specific laboratory markers such as ferritin (>1000 ng/mL for adult-onset Still's disease), LDH, uric acid, and beta-2 microglobulin (for occult lymphoma) were highlighted. The importance of repeat blood cultures for fastidious organisms and targeted biopsies (bone marrow, temporal artery, liver, or excisional lymph node) based on imaging findings was emphasized. Empiric anti-tuberculosis treatment in endemic areas and empiric steroid therapy for adult-onset Still's disease were recommended only under strict clinical and laboratory criteria. Conclusions: A systematic, tiered diagnostic approach incorporating advanced imaging, specific biomarkers, and targeted biopsies is crucial for resolving FUO after an initial negative workup. Careful consideration of regional epidemiology and strict adherence to diagnostic criteria are paramount before initiating empiric therapies, particularly in conditions like tuberculosis and adult-onset Still's disease.

3 contributors 60 votes 6 Apr 2026

TDX-2026-00014

Optimizing Mechanical Ventilation in Obese Patients with Moderate Acute Respiratory Distress Syndrome: A Consensus-Based Approach to Driving Pressure, Plateau Pressure, and Adjunctive Therapies

Mechanical ventilation in patients with Acute Respiratory Distress Syndrome (ARDS) is complex, with obesity presenting unique challenges due to altered respiratory mechanics. This paper synthesizes expert clinical opinions from a specialized medical discussion forum, addressing critical questions regarding ventilator management in obese ARDS patients. The discussion centered on a 55-year-old obese female with moderate ARDS (P/F ratio 142), highlighting the interplay between plateau pressure, driving pressure, and adjunctive strategies. Experts advocate for tolerating higher plateau pressures (up to 33-35 cmH2O) in obese individuals, provided driving pressure remains below 15 cmH2O, acknowledging the significant contribution of chest wall elastance to airway pressure in this population. Driving pressure is emphasized as the primary ventilator target, aligning with evidence suggesting its superior predictive value for mortality. Early prone positioning is strongly recommended for eligible patients, particularly in obesity, due to its enhanced mechanical benefits. The routine use of esophageal balloon manometry for transpulmonary pressure measurement is endorsed, especially in obese patients, to personalize ventilation strategies. Practical considerations for safe prone positioning in obese patients are also detailed. This consensus highlights a shift towards individualized, physiology-guided ventilation, prioritizing transpulmonary and driving pressures while integrating evidence-based adjunctive therapies to mitigate ventilator-induced lung injury and improve outcomes in this challenging patient cohort.

3 contributors 67 votes 6 Apr 2026

TDX-2026-00013

Compartment Pressure Thresholds for Acute Compartment Syndrome in Tibia-Fibula Fractures: A Clinical Consensus and Evidence Synthesis

Acute compartment syndrome (ACS) represents a limb-threatening surgical emergency, frequently associated with closed long bone fractures such as those of the tibia and fibula. The diagnosis of ACS hinges on a combination of clinical findings and objective intracompartmental pressure (ICP) measurements; however, the precise interpretation of ICP thresholds, particularly the debate between absolute pressure values and the delta-P criterion, remains a subject of ongoing clinical contention. This paper synthesizes a clinical discussion originating from a community peer-reviewed platform, involving two expert physicians (Orthopedics & Trauma Surgery, Emergency Medicine) and validated by 46 peer votes, addressing the diagnostic utility of various ICP thresholds, the role of continuous monitoring, and the critical importance of clinical judgment in ACS management. A consensus emerged, strongly advocating for the primacy of clinical findings, such as disproportionate pain and pain on passive stretch, over strict adherence to numerical ICP thresholds. The index case, a 22-year-old male with a closed tibia-fibula fracture, underwent fasciotomy despite a delta-P (diastolic BP - ICP) of 40 mmHg, which typically would not meet traditional surgical criteria. Intraoperative findings confirmed muscle ischemia, and the patient subsequently achieved full functional recovery. Both contributing experts emphasized ICP measurements as an adjunct to clinical assessment and highlighted the significant risks associated with delayed consultation and reliance on an unreliable clinical examination in sedated or obtunded patients. This synthesis underscores that clinical judgment, guided by the classic '5 P's,' should primarily direct the decision for fasciotomy in suspected ACS, even when ICP measurements do not strictly align with established numerical criteria. Timely orthopedic consultation and a heightened awareness of situations compromising clinical assessment are paramount to prevent irreversible ischemic damage and optimize patient outcomes.

2 contributors 46 votes 6 Apr 2026

TDX-2026-00012

Optimizing Malignant Hyperthermia Management: A Peer-Reviewed Consensus on Dantrolene Reconstitution and Crisis Protocols

Background: Malignant Hyperthermia (MH) is a rare, life-threatening pharmacogenetic disorder triggered by volatile anesthetics and succinylcholine. Rapid diagnosis and immediate administration of dantrolene are critical for patient survival. However, the traditional reconstitution process for dantrolene sodium can be time-consuming, potentially delaying definitive treatment during an acute crisis. This paper synthesizes expert opinions on practical solutions to mitigate these delays and optimize overall MH management. Methods: This study utilized a community peer-reviewed clinical Q&A discussion platform, tachyDx, involving two verified physician contributors and garnering 55 peer votes. The discussion focused on practical challenges related to dantrolene reconstitution during suspected MH and parallel management strategies. Expert responses were analyzed to identify consensus and divergent practices regarding dantrolene stocking, availability of concentrated formulations, concurrent therapeutic interventions, and post-crisis monitoring. Results: Key findings include a consensus on increased dantrolene stocking (e.g., 36 vials of classic dantrolene) and the significant advantage of concentrated formulations like Ryanodex for rapid administration. Parallel management strategies emphasized immediate anesthetic cessation, hyperventilation, aggressive active cooling, and prompt treatment of hyperkalemia. Post-crisis care protocols highlighted the necessity for continuous monitoring in an intensive care unit for at least 24 hours, serial laboratory assessments, maintenance dantrolene dosing, and crucial genetic counseling for affected families. Conclusions: Efficient dantrolene administration, supported by adequate stocking, rapid-reconstitution formulations, and well-drilled parallel management protocols, is paramount in MH crisis. Comprehensive post-crisis care, including genetic counseling, is essential for patient safety and family screening. These insights underscore the need for robust institutional protocols and continuous education to improve outcomes in MH.

2 contributors 55 votes 6 Apr 2026

TDX-2026-00011

Management of Incidental Part-Solid Pulmonary Nodules: A Community-Based Clinical Consensus on Fleischner 2017 Guidelines and PET-CT Utility

Background: Incidental pulmonary nodules are frequently detected on computed tomography (CT) scans performed for unrelated indications, posing a significant clinical challenge regarding their malignant potential and appropriate management. Part-solid nodules, in particular, carry a higher risk of malignancy compared to pure ground-glass or solid nodules, necessitating careful surveillance strategies. The Fleischner Society 2017 guidelines provide evidence-based recommendations for their management, yet clinical scenarios often present nuances that require expert interpretation and communication. Methods: This study synthesizes expert opinions from a peer-reviewed clinical Q&A platform (tachyDx), involving two verified physicians (a radiologist and a pulmonologist) and 43 community peer votes. A specific clinical case of a 48-year-old non-smoker with an incidental 7mm part-solid pulmonary nodule (4mm solid component) was presented to elicit consensus on guideline adherence, solid component thresholds for intervention, utility of PET-CT, and inter-specialty communication. Results: A strong consensus emerged for strict adherence to Fleischner 2017 guidelines for initial surveillance of sub-centimeter part-solid nodules with small solid components. The solid component size was identified as the primary determinant for risk stratification, with PET-CT deemed unhelpful for sub-centimeter lesions due to resolution limitations. Emphasis was placed on clear, structured communication of findings and the importance of early shared decision-making to address patient anxiety. Conclusions: The findings underscore the critical role of Fleischner 2017 guidelines in managing incidental part-solid pulmonary nodules. They highlight the limited utility of PET-CT for sub-centimeter lesions and advocate for patient-centered communication strategies, integrating clinical judgment with established guidelines.

2 contributors 43 votes 6 Apr 2026

TDX-2026-00010

Differential Diagnosis and Management of Neuroleptic Malignant Syndrome and Serotonin Syndrome in Polypharmacy: A Clinical Case and Community Consensus

Neuroleptic Malignant Syndrome (NMS) and Serotonin Syndrome (SS) represent life-threatening adverse drug reactions with significant clinical overlap, posing a considerable diagnostic challenge, particularly in patients receiving multiple psychotropic medications. This paper presents a detailed analysis of a 45-year-old male on haloperidol and fluoxetine who developed severe hyperthermia, rigidity, altered mental status, and elevated creatine phosphokinase (CPK), necessitating urgent differentiation and management. Through a community peer-reviewed clinical discussion involving two verified physicians and 59 peer votes, a consensus was reached on diagnostic criteria and therapeutic strategies. Key distinguishing features identified included the presence of lead-pipe rigidity and bradykinetic facies, a significantly elevated CPK level (12,400 U/L, peaking at 18,000 U/L), and a subacute onset over several days, which collectively favored a diagnosis of NMS. Management involved immediate discontinuation of all suspected agents, aggressive supportive care including intravenous hydration and cooling, and the initiation of dantrolene. The patient demonstrated clinical improvement with normalization of temperature and mental status, and resolution of renal dysfunction. This case highlights the critical importance of meticulous clinical assessment and a structured approach to management in complex neuroleptic- and serotonergic-induced toxicities, emphasizing the utility of specific pharmacological interventions tailored to the suspected syndrome while maintaining robust supportive care.

2 contributors 59 votes 6 Apr 2026

TDX-2026-00009

Management of Phenobarbital-Resistant Neonatal Seizures in Hypoxic-Ischemic Encephalopathy: A Community Peer-Reviewed Clinical Consensus

Background: Neonatal seizures, particularly in the context of hypoxic-ischemic encephalopathy (HIE), represent a significant neurological emergency. Despite phenobarbital being the established first-line anticonvulsant, a substantial proportion of neonates exhibit refractory seizures, necessitating the judicious selection of second-line agents. Optimal management strategies for these challenging cases, including appropriate antiepileptic drug (AED) dosing, electroencephalographic monitoring targets, and pharmacokinetic considerations during therapeutic hypothermia, remain areas of ongoing clinical discussion. Methods: This paper synthesizes a peer-reviewed clinical discussion initiated on the tachyDx platform. A clinical scenario involving a 3-day-old term neonate with HIE Grade II experiencing phenobarbital-resistant seizures during therapeutic hypothermia was presented. Two verified physician experts provided detailed responses, which subsequently garnered 49 community peer votes. Results: Levetiracetam was identified as the preferred second-line agent over phenytoin, citing its comparable efficacy to phenobarbital in some studies and a more favorable side effect profile in neonates. Recommended levetiracetam dosing included a 40-60 mg/kg intravenous load followed by 10-30 mg/kg/day maintenance in divided doses. Consensus indicated a goal of electrographic seizure freedom on amplitude-integrated electroencephalography (aEEG) if achievable without excessive sedation, with a threshold for escalating therapy defined as continuous seizure activity exceeding 50% of a 1-hour epoch. However, caution was advised against over-treatment of isolated, brief electrographic events. Therapeutic hypothermia was noted to reduce hepatic metabolism by approximately 25%, impacting phenobarbital levels, while levetiracetam, being primarily renally cleared, was less affected, though mild reductions in glomerular filtration rate were acknowledged. Conclusions: This expert consensus provides practical guidance for managing phenobarbital-resistant neonatal seizures in HIE. Levetiracetam emerges as a favored second-line option, with specific dosing and aEEG monitoring strategies outlined. The critical influence of therapeutic hypothermia on AED pharmacokinetics necessitates careful monitoring and dose adjustments. These findings underscore the importance of individualized, evidence-informed approaches to optimize neurodevelopmental outcomes.

2 contributors 49 votes 6 Apr 2026

TDX-2026-00008

Management of Steroid-Refractory Immune Checkpoint Inhibitor-Associated Hepatitis: A Multidisciplinary Clinical Consensus and Case Report

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but are associated with immune-related adverse events (irAEs), including hepatitis. Management of steroid-refractory ICI-associated hepatitis presents a significant clinical challenge. This paper synthesizes expert opinion from a peer-reviewed clinical discussion platform, augmented by established medical literature, to provide guidance on managing a case of Grade 3 nivolumab-induced hepatitis refractory to initial corticosteroid therapy. **Methods:** A clinical scenario detailing a 62-year-old male with nivolumab-induced Grade 3 steroid-refractory hepatitis was posted on a specialized physician-to-physician Q&A platform (tachyDx). Two verified physicians, an oncologist and a gastroenterologist/hepatologist, contributed expert responses, which garnered 62 community peer votes. These responses were analyzed and integrated with current evidence-based guidelines and landmark clinical trials. **Results:** Consensus recommendations included mycophenolate mofetil (MMF) as the preferred second-line immunosuppressant, with tacrolimus as a potential addition for further refractory cases. Liver biopsy was deemed essential in steroid-refractory settings to confirm diagnosis and exclude alternative etiologies. Rechallenge with the same ICI for Grade 3 hepatitis was generally not recommended due to high recurrence rates. Management of the underlying non-small cell lung cancer (NSCLC) involved bridging chemotherapy while immunosuppression was ongoing. **Conclusions:** This case highlights the critical need for a multidisciplinary approach to steroid-refractory ICI-associated hepatitis. Early initiation of second-line immunosuppression, guided by liver biopsy, and careful consideration of cancer therapy continuation are paramount for optimizing patient outcomes.

2 contributors 62 votes 6 Apr 2026

TDX-2026-00007

Optimizing Bedaquiline-Based Regimens for Pre-Extensively Drug-Resistant Tuberculosis in HIV Co-infection: A Community Peer-Reviewed Clinical Consensus

Background: Pre-extensively drug-resistant tuberculosis (pre-XDR TB), characterized by resistance to isoniazid, rifampicin, and fluoroquinolones, presents a significant global health challenge, particularly in individuals co-infected with human immunodeficiency virus (HIV). The advent of novel anti-TB agents and shorter regimens, such as bedaquiline-pretomanid-linezolid (BPaL), offers improved outcomes but necessitates careful consideration of regimen composition, drug dosing, adverse event monitoring, and drug-drug interactions. Methods: This study synthesizes expert clinical opinion derived from a peer-reviewed clinical Q&A platform (tachyDx), involving two verified physicians and garnering 54 community peer votes. A clinical scenario involving a 34-year-old female with pre-XDR TB and HIV co-infection was presented, prompting discussion on regimen selection, linezolid management, QTc monitoring, antiretroviral therapy (ART) timing, and drug interactions. The accepted answer and additional insights were critically analyzed to establish a consensus. Results: The BPaL regimen was strongly favored for its shorter duration and high efficacy, contingent on pretomanid availability. Optimal linezolid dosing was identified as 600 mg daily for 26 weeks, with rigorous hematologic and neurologic monitoring. A comprehensive QTc monitoring protocol for bedaquiline, particularly in the context of dolutegravir (DTG) co-administration, was outlined. Continuation of existing ART was recommended, with specific guidance for ART-naïve patients. Critical drug-drug interactions, including those involving CYP3A4 inhibitors/inducers and monoamine oxidase inhibitors, were highlighted. Conclusions: This expert consensus provides practical, evidence-informed guidance for managing pre-XDR TB in HIV co-infected patients, emphasizing the BPaL regimen, meticulous adverse event monitoring, and proactive management of drug interactions. These recommendations aim to facilitate the safe and effective implementation of novel TB therapies in complex clinical settings.

2 contributors 54 votes 6 Apr 2026
Page 1 of 2Next →

Topics

Allpharmacology8critical-care7cardiology6emergency-medicine6oncology5pulmonology5nephrology4neurology4gastroenterology3immunology3hematology3surgery3infectious-disease3radiology2endocrinology2anesthesiology2hepatology2pediatrics2rheumatology2evidence-based-medicine1orthopedics1trauma1neonatology1psychiatry1internal-medicine1